Dr. Rafii is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4510 Executive Dr
San Diego, CA 92121Phone+1 858-657-8540Fax+1 858-657-8557
Education & Training
- Johns Hopkins UniversityResidency, Neurology, 2003 - 2006
- Johns Hopkins UniversityInternship, Internal Medicine, 2002 - 2003
- The Warren Alpert Medical School of Brown UniversityClass of 2002
Certifications & Licensure
- CA State Medical License 2006 - 2026
- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext Start of enrollment: 2013 Mar 01
- Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo Start of enrollment: 2013 Jul 01
- Down Syndrome Biomarker Initiative (DSBI) Start of enrollment: 2013 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 89 citationsAlzheimer's disease associated with Down syndrome: a genetic form of dementia.Juan Fortea, Shahid Zaman, Sigan L. Hartley, Michael S. Rafii, Elizabeth Head
The Lancet. Neurology. 2021-11-01 - 68 citationsAgrin in Alzheimer's Disease: Altered Solubility and Abnormal Distribution within Microvasculature and Brain ParenchymaJohn E. Donahue, Tyler M. Berzin, Michael S. Rafii, David J. Glass, George D. Yancopoulos
Proceedings of the National Academy of Sciences of the United States of America. 1999-05-25 - 55 citationsEarly-stage Alzheimer disease: getting trial-ready.Paul S Aisen, Gustavo A Jimenez-Maggiora, Michael S Rafii, Sarah Walter, Rema Raman
Nature Reviews. Neurology. 2022-07-01
Journal Articles
- Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer DiseaseReisa Sperling, Michael S Rafii, Gary Romano, JAMA Neurology
Press Mentions
- Alzheimer's Meds Are Here. But for the down Syndrome Community, It's Still the 1980sMarch 1st, 2023
- Top Dementia Scientists Present Key Findings, InitiativesNovember 28th, 2022
- It’s Not a Normal Sign of Aging: Mild Cognitive Impairment Takes TollApril 19th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: